Adagene gets NMPA clearance for HER2xCD3 bispecific ADG138
China's drug regulator cleared the IND for the double-masked T-cell engager, with a first-in-human Phase 1 study expected to start in China in the fourth quarter of 2026.
SEC filing
3 stories
China's drug regulator cleared the IND for the double-masked T-cell engager, with a first-in-human Phase 1 study expected to start in China in the fourth quarter of 2026.
SEC filing
Adagene disclosed a lead candidate selection under its expanded Third Arc Bio deal and a $2.0 million preclinical milestone payment from Exelixis tied to its SAFEbody platform.
SEC filing (2)